Individualised treatment of COPD exacerbations using biomarkers

Ugeskr Laeger. 2024 Apr 1;186(14):V09230560. doi: 10.61409/V09230560.
[Article in Danish]

Abstract

This review highlights key aspects of treating chronic obstructive pulmonary disease (COPD) exacerbation, focusing on the optimisation of systemic corticosteroid and antibiotic use through personalised treatment using biomarkers. Eosinophil-guided therapy reduces corticosteroid usage which might reduce side effects, while procalcitonin-guided therapy contributes to reduced antibiotic consumption. These approaches, documented through well-conducted randomized controlled trials, suggest the possibility of enhancing COPD exacerbation management, reducing potential side effects, and addressing concerns related to antibiotic resistance.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Biomarkers
  • Disease Progression
  • Glucocorticoids / therapeutic use
  • Humans
  • Pulmonary Disease, Chronic Obstructive* / drug therapy
  • Randomized Controlled Trials as Topic

Substances

  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents
  • Biomarkers
  • Glucocorticoids